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We analyzed T cell subsets from cryopreserved PBMC obtained from the TrialNet
Pathway to Prevention archives. We compared subjects who had previously
seroconverted for one or more autoantibodies with non-seroconverted, autoantibody
negative individuals. We observed a reduced frequency of MAIT cells among
seroconverted subjects. Seroconverted subjects also possessed decreased frequencies
of CCR4-expressing CD4T cells, including a regulatory-like subset. Interestingly, we
found an elevation of CD57+, CD28–, CD127–, CD27– CD8T cells (SLEC) among
seroconverted subjects that was most pronounced among those that progressed to
disease. The frequency of these SLEC was strongly correlated with CMV IgG abundance
among seroconverted subjects, associated with IA-2 levels, and most elevated among
CMV+ seroconverted subjects who progressed to disease. Combined, our data indicate
discrete, yet profound T cell alterations are associated with islet autoimmunity among
at-risk subjects.
Keywords: type 1 diabetes (T1D), mucosal associated invariant T cells (MAIT), CD4 T cells, CD8 T cells, TrialNet,
autoimmunity, T regulatory cells (Treg), cytomegalovirus—HCMV
INTRODUCTION
Human type 1 diabetes (T1D) is characterized by the presence of antibodies targeting islet cell-
associated antigens (i.e., autoantibodies) and the selective destruction of beta cells resulting in
insulin deficiency (1). The destruction of beta cells is widely believed to be driven by autoreactive
T cells (2). The evidence for this theory is generally indirect, comprising multiple reports of a
variable T cell presence in and around islets [see for example (3)], including islet-antigen reactive
CD8T cells (4). Furthermore, islet-antigen reactive CD8T cells have been isolated from the
peripheral blood of type 1 diabetics and these can be induced to destroy beta cells in culture (5).
In vivo, this unimpeded destruction by autoreactive CD8T cells is considered to indicate an escape
from tolerance, possibly due to dysfunctional regulatory T cells (Treg) among diabetics (6).
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Defining the prodromal events which ultimately manifest in
clinically-defined T1D remains a critical area of research. It is
known that autoantibody presence often occurs several years
prior to diagnosis (7), with functional aberrancy and reduction
in the beta cell population preceding overt hyperglycemia (8, 9).
While genetic factors can identify some risk, environmental
variables are the ostensible drivers of T1D and its rising rate
of incidence (10–12). In the absence of a well-characterized
environmental trigger that may be avoided, early intervention
following seroconversion is a worthy clinical goal for at-
risk subjects (13). To that end, a thorough investigation of
immune cells during the preclinical period is warranted. Such
an investigation can reveal immune perturbations indicative of
environmental exposures and/or regulatory dysfunction. These
data can then be used to define biomarkers indicating risk, in
the design of therapeutics, and in the unraveling of autoimmune
mechanisms leading to beta cell decline.
Although a simply stated need, the identification of at-
risk subjects with subsequent leukocyte isolation is a near
Herculean labor. Importantly, an ongoing collaboration was
established to meet this challenge. The T1D TrialNet Pathway to
Prevention Study involves screening relatives of type 1 diabetics
for autoantibodies to gauge risk, as well as a component for
biosample acquisition (14). We utilized TrialNet PBMC samples
to explore the hypothesis that peripheral T cell abundance
is altered among seroconverted, at-risk subjects. We used
flow cytometry to interrogate multiple T cell populations
using a range of differentiation and lineage markers. Our
results demonstrate profound changes in frequency of T cell
subsets are associated with seroconversion, with several T cell
lineages impacted including regulatory-like (Treg-like), cytotoxic
(CD8), and mucosal associated invariant T (MAIT) cells. These
data suggest substantial immunodeficiency underrides a likely
pathogen response among seroconverted subjects.
MATERIALS AND METHODS
Patient Samples
Cryopreserved PBMC were acquired as part of an ancillary
study approved by TrialNet from the Pathway to Prevention
study of 1st and 2nd degree relatives of individuals with type
1 diabetes. Aside from the familial association, study eligibility
is limited to those 1st and 2nd degree relatives who are not
on medication to control hyperglycemia, not currently using
immunosuppressive or immunomodulatory agents, have no
known severe active disease, and do not have diabetes or a
history of diabetes. From this pool of subjects, we received 79
blinded samples comprising 3 subgroups of subjects. Twenty-
five samples were from autoantibody negative (AA–) 1st and 2nd
degree relatives of diagnosed type 1 diabetics or seroconverted,
at-risk individuals. Having no autoantibodies, yet sharing some
environmental and genetic risk, these samples constitute our
control group. Importantly, these AA– subjects were not
related to the seroconverted, at-risk individuals analyzed in our
study. The remaining 54 subjects, labeled “seroconverted,” had
previously seroconverted for one or more autoantibodies and
are at increased risk of developing T1D (15, 16). Autoantibody
testing was performed by TrialNet. Individuals are screened
for GAD65, IA-2, and IAA. If any of these measurements
were positive, they were also then screened for ZnT8 and ICA.
Positivity thresholds were as follows: IAA, >0.010; GAD65,
>0.032; ICA512, >0.049; GAD65H, >20; IA-2H, >5; ZnT8,
>0.020; ICA, ≥10. Once an individual has tested positive for
an autoantibody twice within one year, they are considered
“autoantibody positive” or seroconverted to the production of
autoantibodies targeting islet antigens. Among the seroconverted
subset, 26 samples were from individuals who have not yet
progressed to clinical disease, and for our analysis these are
labeled “non-progressor.” The remaining 28 samples were from
individuals who ultimately progressed to clinical disease. This
subgroup is labeled as “progressor.” Our request for samples from
TrialNet did not specify particular HLA-risk alleles, therefore our
sample set constituted a mix of HLA types. Although we did
request samples from subjects between 8 and 11 years old, upon
unblinding the samples we discovered our subjects spanned a
much broader age range. Patient data is presented in Table 1.
Flow Cytometry
Surface panel design and analysis was performed using a BD LSR
II equipped with 5 lasers: UV (355 nm) for Brilliant Ultraviolet
(BUV) 395 and 737 and LiveDead UV Blue; Violet (405 nm)
for Brilliant Violet (BV) 421, 510, 605, 650, 711, and 785; Blue
(488 nm) for FITC and PerCP-Cy5.5; Yellow-Green (561 nm)
for PE, PE-CF594, and PE-Cy7; and Red(633 nm) for APC and
Alexa Fluor(AF) 700. The following antibodies and reagents were
used: from Biolegend CCR7(PE, clone G043H7), CCR4(PE-Cy7,
clone L291H4), CD14(BV711, clone M5E2), CD19(BV711, clone
HIB19), CD27(BV785, clone O323), CD57(FITC, clone HCD57),
CD45RA(PerCP-Cy5.5, clone HI100), Vα7.2(BV605, clone
3C10), CD45(AF700, clone HI30), Streptavidin-APC; from BD
Biosciences CXCR5(BV421, clone RF8B2), CD3(BUV737, clone
UCHT1), CD4(BUV395, clone RPA-T4), CD8(BV510, clone
RPA-T8), CD28(PE-CF594, clone CD28.2), CD161(BV650,
TABLE 1 | Patient data.
Status n (n
female)
Variable Mean SD Median Min Max
AA- 25 (11) Age 12.2 2.7 12.0 7.7 16.9
BMI 19.7 5.4 18.7 14.5 35.6
HbA1c 5.1 0.3 5.1 4.5 5.6
Seroconverted 54 (23) Age 10.9 4.6 10.3 4.7 26.8
BMI 20.4 5.5 19.1 14.0 45.7
HbA1c 5.1 0.3 5.1 4.3 6.0
Seroconverted Non-
progressor
26 (10) Age 10.6 4.0 9.9 4.8 21.8
BMI 19.8 4.6 18.2 14.0 29.8
HbA1c 5.0 0.3 4.9 4.5 5.8
Progressor 28 (13) Age 11.3 5.1 10.8 4.7 26.8
BMI 21.1 6.2 20.7 14.8 45.7
HbA1c 5.2 0.4 5.3 4.3 6.0
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clone DX12); from eBioscience CD127(Biotin, clone eBioRDR5);
from life technologies LiveDead UV Blue. Cryopreserved PBMC
were thawed and rested overnight in X-VIVO 15 (Lonza)
supplemented with human AB serum (MP Biomedicals) at 2%
v/v at 37◦ C with 5% CO2. Samples were then counted and
distributed to 96 well plates for labeling following methods
described previously (17) with two modifications: Fc receptors
were blocked using human IgG (Sigma Aldrich) and antibody
cocktails were prepared using Brilliant Stain Buffer (BD
Biosciences).
For FOXP3 analysis, lymphocytes from healthy human
donors were acquired from the UNMC elutriation core
facility, cryopreserved, thawed, rested and surface labeled
as described above. We then utilized the True-Nuclear
Transcription Factor Buffer set (BioLegend) according to
manufacturer’s recommendations. In panel validation, we
compared PE-conjugated FOXP3 clones 206D (BioLegend),
PCH101 (eBioscience), and 259D/C7 (BD Biosciences) and clone
206D gave the greatest signal-to-noise ratio (data not shown).
The final panel included the aforementioned FOXP3, CD25
(VioBright FITC, clone 4E3, Miltenyi), and the conjugated-
clones and reagents listed above for LiveDead, CD3, CD4,
CXCR5, CCR4, and CD127 with streptavidin-APC.
Data analysis was conducted in a blinded fashion using FlowJo
(v10.2, TreeStar). All samples were pregated to exclude doublets,
debris, dead cells, and non T cells (lineage negative) and then
multiple subsets were identified and gated according to known T
cell differentiation pathways. A representative gating procedure
for all subsets explored is shown in Supplemental Figure 1.
Following analysis, raw data files and tabular results were
uploaded to TrialNet, upon which we received sample
identification, clinical data, and autoantibody levels in order to
perform statistical analysis.
Measurement of Anti-viral
Immunoglobulins
We received blinded vials of plasma from the majority
of the subjects in our PBMC analysis: 25/25 AA–, 23/26
non-progressors, and 27/28 progressors. Prior to performing
assays, the vials of plasma were thawed, divided into several
aliquots, refrozen, and stored at −80◦C in order to run
several assays and limit sample degradation from multiple
freeze/thaw cycles. The following anti-viral immunoglobulin
ELISAs from IBL America were performed according to
manufacturer’s directions: CMV IgM (IB19206), CMV IgG
(EG101), EBV VCA IgM (IB79231), EBV VCA IgG (IB79230),
enterovirus IgM(IB05053), and enterovirus IgG(IB05052). All
sample dilutions containedHeteroblock (Omega Biologicals Inc.)
to eliminate potential interference resulting from the presence
of heterophilic antibodies. Optical densities were measured
using a Synergy H1 Hybrid Multi-Mode Reader (BioTek
Instruments, Inc.). Sample positivity for viral immunoglobulins
FIGURE 1 | Seroconverted subjects have reduced frequencies of MAIT cells. (A) Starting from total T cells, MAIT cells were identified as Vα7.2+, CD45RA-, CD161+,
CCR7dim/−, CD28+, CD127+ events. (B) Seroconverted subjects have reduced frequencies of MAIT cells in comparison to AA– subjects. Reduced frequencies
were most acute in the CD8+, CD4– (CD8+), and CD8–, CD4– (DN) compartments (Supplemental Figure 2). (C) Upon dividing seroconverted subjects according
to disease progression, we observed that reduced frequencies of MAIT cells were most prominent among non-progressors. (D) Descriptive statistics for the frequency
of MAIT cells of total T cells for all groups compared. For figures (B,C), bars represent median. Statistical tests fully described in section Materials and Methods.
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was determined following calculations defined per assay. If
sample positivity was equivocal, the sample was retested. If the
sample was also equivocal on the follow-up test, it was labeled as
“gray” for purposes of stratification and treated as negative. Upon
completion of our plasma analysis, tabular data was uploaded to
TrialNet. We then received sample identification data for pairing
with our PBMC results and subsequent statistical analysis.
Statistics
For mean comparisons, natural log transformation was applied
to the data prior to analysis. For comparison of two groups,
we used Student’s T-test and for comparisons of three
groups, we used analysis of variance (ANOVA). If the results
of the ANOVA were significant, then pairwise comparisons
were made, adjusting for multiple comparisons with Tukey’s
method. For correlations, data were not transformed and
we used Spearman’s Rank-Order correlation. In all cases,
figures and descriptive data depict non-transformed data
to facilitate interpretation. Figures were made using Prism
(v6.03 GraphPad Software Inc.), and data was analyzed using
Prism and SAS software versions 9.4 (SAS Institute Inc.,
Cary, NC).
RESULTS
Reduced Frequencies of Mucosal
Associated Invariant T Cells (MAIT)
in Seroconverted Subjects
MAIT cells are regularly found in human blood, the liver, and
the gastrointestinal mucosa (18), and respond to microbially-
derived vitamin B metabolites presented through MR1 (19).
MAIT cells are capable of directly lysing bacterially-sensitized
and infected target cells (20, 21) and can produce the
proinflammatory cytokines IFN-γ, TNF-α, and IL-17 (18).
Phenotypically, in the absence of MR1-loaded multimers,
MAIT cells are unambiguously identifiable in blood by the high
CD161 expression, presence of Vα7.2 T cell receptor, and T cell
lineagemarker CD3 (18, 22). The circulatingMAIT cell lineage in
healthy subjects is also regularly CD28+, CD127+, CD45RAlow,
and CCR7low (18, 23), but exceptions to this phenotype do exist
in certain disease states [e.g., chronic HIV (24)], as well as in fetal
tissue and cord blood (25, 26). MAIT cells are generally CD8+
(∼85%) with the remaining being chiefly DN (CD4–, CD8–),
although CD4+ and DP (CD4+, CD8+) groups are frequently
observable in scant amounts in healthy donors. The functional
differences among these MAIT cell subsets have not been fully
FIGURE 2 | Seroconverted subjects have reduced frequencies of CD45RA+, CCR7dim memory-like CD8T cells. (A) Starting from total CD8T cells. CD45RA+,
CCR7dim memory-like CD8T cells were identified as CD28+, MAIT–, CCR4–, CXCR5–, CD127+/high, CCR7
dim, CD27+, CD57–, and CD45RA+. (B) Seroconverted
subjects have reduced frequencies of CD45RA+, CCR7dim memory-like CD8T cells in comparison to AA- subjects. Reduced frequencies of CD45RA+, CCR7–
memory-like CD8T cells were also observed (Supplemental Figure 3). (C) Upon dividing seroconverted subjects according to disease progression, we observed
that reduced frequencies of CD45RA+, CCR7dim memory-like CD8T cells were most prominent among non-progressors. (D) Descriptive statistics for the frequency
of CD45RA+, CCR7dim memory-like CD8T cells of total T cells for all groups compared. For figures (B,C), bars represent median. Statistical tests fully described in
section Materials and Methods.
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FIGURE 3 | Seroconverted subjects have elevated frequencies of short-lived effector-like cells (SLEC) and this expansion was most prominent among those that
progressed to disease. (A) Starting from total CD8T cells, SLEC were identified as CD28–, CD57+, CD27–, and CD127–. (B) Seroconverted subjects have increased
frequencies of SLEC in comparison to AA– subjects. (C) Upon dividing seroconverted subjects according to disease progression, we observed that elevated
frequencies of SLEC were most prominent among progressors. (D) Descriptive statistics for frequency of SLEC of total T cells for all groups compared. For figures
(B,C), bars represent median. Statistical tests fully described in section Materials and Methods.
clarified, although it has recently been reported that the CD8+
subset possesses somewhat greater effector potential than the DN
subset (27).
We identified total MAIT cells as CD3+, Vα7.2+, CD161+,
CD45RAlow, CCR7low, CD28+, CD127+ events and also
divided them by CD4 and CD8 expression (Figure 1A). With
this approach, we observed a sharply reduced frequency of
MAIT cells among seroconverted individuals (Figures 1B,D).
This reduction extended into all MAIT cell subsets as
defined by CD4 and CD8 expression, and appeared most
acute within the major compartments identified as CD8+
and DN (Supplemental Figures 2A,B). When evaluating the
seroconverted subjects according to disease progression, we
found the non-progressors harbored the fewest MAIT cells,
while the reduction among the progressors was not significant
(Figures 1C,D). These data indicate that a MAIT cell reduction
is associated with seroconversion and this effect is slightly
ameliorated among those who progress to disease.
Short-Lived Effector-Like CD8T Cells Are
Expanded in Seroconverted Individuals
and This Is Most Pronounced Among
Those Who Progressed to Disease
Conventional αβ CD8T cells are the chief cytotoxic arm of
adaptive immunity. Upon licensing and activation, CD8T cells
rapidly proliferate in order to destroy microbially-infected or
transformed cells (28). Following the eradication of targets,
effector cells die off while memory populations remain in tissue
and circulation. This memory provides a quick recall response
to repeat offenders and is considered a hallmark of T cell
immunity. Outside of this role as defenders, CD8T cells have
been incriminated in the pathogenesis of several autoimmune
diseases (29).
In our analysis of CD8T cells, we first divided CD8T cells
according to presence or absence of costimulatory protein
CD28. Among the CD28+ CD8T cells, we removed MAIT cells
and analyzed the remaining CD8T cells for expression levels
of CCR4, CXCR5, CD45RA, CD27, CD127, CCR7, and
CD57. Similar to what was observed among MAIT cells,
seroconverted subjects possessed reduced proportions of
CD45RA+, CCR7dim/−, CD57–, CD27+, CD127high, CXCR5–,
CCR4– CD8T cells compared to AA– subjects (Figures 2A,B,D
and Supplemental Figure 3). This combination of markers can
best be described as a CD45RA+ memory subset following
current differentiation paradigms (30, 31). Upon dividing the
seroconverted into non-progressor and progressor subsets, we
found that the non-progressors were significantly reduced in
proportion, while the progressors did not approach significance
(Figures 2C,D and Supplemental Figure 3).
The absence of CD28 on human T cells is indicative of
chronic stimulation (32). We divided CD28- CD8T cells
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FIGURE 4 | Seroconverted subjects have reduced frequencies of CCR4+, CD127bright memory CD4T cells. (A) Starting from total MAIT– CD4T cells, CD127bright
memory T cells were identified as CCR4+, CXCR5–, CCR7–, CD27+, CD127bright events. (B) Seroconverted subjects have reduced frequencies of CD127bright
memory CD4T cells in comparison to AA– subjects. CCR4-expressing terminally differentiated and T follicular helper-like CD4T cells were also reduced in frequency
(Supplemental Figure 4). (C) Upon dividing seroconverted subjects according to disease progression, we observed that reduced frequencies of CD127bright
memory CD4T cells were most prominent among non-progressors. (D) Descriptive statistics for the frequency of CD127bright memory CD4T cells of total T cells for
all groups compared. For figures (B,C), bars represent median. Statistical tests fully described in section Materials and Methods.
by expression of CD57, CD127, and CD27 to characterize
this antigen-experienced compartment. Our analysis
revealed an elevated frequency of CD127–, CD27–,
CD57+, CD28– CD8T cells among seroconverted subjects
(Figures 3A,B,D). This combined phenotype indicates
terminal differentiation, cytotoxic potential via perforin
production, and short-lived status (33–36). Thus, we
abbreviated their phenotype as SLEC for short-lived effector-
like cells. Intriguingly, this expansion of SLEC was most
prominent among progressors (Figures 3C,D), suggesting
an acute pathogen response may be associated with disease
progression.
CCR4-Expressing CD4T Cell Subsets,
Including CD127dim Treg-Like Cells, Are
Reduced in Seroconverted Subjects
C-C chemokine receptor 4 (CCR4) expression amongCD4T cells
suggests previous T cell receptor engagement (37, 38) as well as
chemotactic responsiveness to thymus and activation-regulated
chemokine (TARC), macrophage-derived chemokine (MDC),
and chemokine like factor 1 (CKLF1) (39–41). Rather than solely
indicating “Th2” status, CCR4– expressing CD4T cells can be
enriched for IFN-γ, IL-22, IL-17, and/or IL-4 production, as well
as possess regulatory function (42–46).
Our analysis of CD4T cells from TrialNet donors revealed
reductions in frequency of three CCR4– expressing subsets
among seroconverted subjects. Memory (CD127bright,
CD27+, CCR7–, CCR4+, CXCR5–; Figures 4A–D), Treg-like
(CD127dim, CD27+, CCR7–, CCR4+, CXCR5–; Figures 5A–D),
and T follicular helper-like (CCR4+, CXCR5+, CD161–;
Supplemental Figure 4) CD4T cell subsets were all reduced
among seroconverted subjects. For each compartment,
the reduction in frequency was most profound among
non-progressors and approached “normal” levels among
progressors.
As our T cell panel did not include CD25 nor FOXP3,
we were unable to cross-confirm regulatory phenotype
among the Treg-like, CCR4-expressing CD4T cells that we
observed contracted among TrialNet samples. However, we
analyzed CD4T cells from 3 healthy human donors and
found that the CCR4+, CXCR5– compartment possesses
a substantial FOXP3+, CD25+ subset, which is also
CD127dim/−, a combined phenotype indicating regulatory
potential (Figure 6). This is in agreement with previous studies
indicating CCR4+ and CD127dim/low CD4T cells contain
Tregs (47–49). Thus, it’s highly likely that the observed
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FIGURE 5 | Seroconverted subjects have reduced frequencies of CCR4+, CD127dim Treg-like CD4T cells. (A) Starting from total MAIT– CD4T cells, CD127dim
Treg-like cells were identified as CCR4+, CXCR5–, CCR7–, CD27+, CD127dim events. (B) Seroconverted subjects have reduced frequencies of CD127dim Treg–like
cells in comparison to AA– subjects. (C) Upon dividing seroconverted subjects according to disease progression, we observed that reduced frequencies of CD127dim
Treg-like CD4T cells were most prominent among non-progressors. (D) Descriptive statistics for the frequency of CD127dimTreg-like CD4T cells of total T cells for all
groups compared. For figures (B,C), bars represent median. Statistical tests fully described in materials and methods.
Treg-like CCR4+ CD4T cells we found to be reduced
among seroconverted subjects contains T cells with regulatory
potential.
Frequencies of CD127dim Treg-Like Cells
Are Positively Correlated With CD127bright
Memory CD4T cells, While CD45RA+,
CCR7dim Memory CD8T Cells and SLEC
Are Positively Correlated With Islet
Autoimmunity
We observed altered frequencies of MAIT, CCR7dim/−
CD45RA+ CD8 memory, SLEC, and CCR4+ CD4T cells,
including memory and Treg-like subsets. As mentioned
previously, it’s widely presumed that T1D is driven by
autoreactive CD8T cells which have escaped tolerance.
Since Tregs can effectively suppress T cell proliferation
in vitro (50), it’s plausible that such subsets may impact
T cell expansions and contractions in vivo. Therefore,
we examined some of the CD4 and CD8T cell subsets
described above for relationships with our CD127dim Treg-like
subset.
First, we compared frequencies of T cell subsets using
Spearman’s Rank-order correlation. We observed no
significant correlations among CD127dim Treg-like CD4T cells
with either MAIT cells, SLEC CD8T cells or CCR7dim,
CD45RA+ CD8T cells (Figures 7A,C,D). Alternatively, among
seroconverted subjects CD127bright memory CD4T cells were
positively and significantly correlated with the frequency of
CD127dim Treg-like CD4T cells, while there was no significant
relationship among AA– subjects (Figure 7B). Further division
of the seroconverted group into non-progressor and progressor
demonstrated similar strong and significant positive correlations
among both groups (data not shown). In total, these correlation
data suggest that the frequency dynamics of the CD127dim
Treg-like cells do not negatively regulate frequencies of
the noted T cell compartments in the periphery. However,
they do demonstrate comparable and unique dynamics for
CD127bright memory CD4T cells and CD127dim CD4T cells
among only the seroconverted subjects. This could be due to
similar effects driving the reductions observed in these two
subsets.
In addition to the correlations comparing frequency of T cell
subsets, we also examined relationships between autoantibody
levels and frequency of T cells. Such a correlation could
reveal if any of these subsets are associated with islet
immunity. Interestingly, we observed a positive and significant
correlation with islet cell antibody (ICA)values and the CCR7dim
CD45RA+, CD8T cell subset (Figure 7E). Furthermore, we
found that the SLEC subset was positively and significantly
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FIGURE 6 | CCR4+, CXCR5– CD127dim CD4T cells possess a regulatory
phenotype. A substantial population of FOXP3+, CD25high events resides in
the CXCR5–, CCR4+ subset. These FOXP3+ events generally exhibited low
CD127 expression. Data is representative of 3 healthy subjects analyzed.
correlated with harmonized insulinoma antigen 2 (IA-2H)
levels (Figure 7F). We observed no significant correlations
among other T cell subsets with autoantibody levels (data not
shown).
Seroconverted Subjects Have Significantly
Elevated Ratios of SLEC to Both CD127dim
Treg-Like Cells and MAIT Cells
Along with these correlations, we examined ratios of frequency
of effectors to frequency of regulators. Here, MAIT cells were
hypothesized to function as either effector or regulator,
as a recent report has suggested MAIT cells may have
a regulatory function (51). We observed that the ratios
of SLEC to CD127dim or MAIT cells were significantly
elevated among seroconverted, as well as when divided
among non-progressors and progressors (Figures 8A,B,G,H).
Alternatively, the ratio of MAIT cells to CD127dim was
relatively similar when comparing AA- and seroconverted
subjects, including progressors and non-progressors
(Figures 8C,D). The ratio of CCR7dim CD45RA+ CD8T cells
to CD127dim CD4T cells was also similar among AA– and
seroconverted subjects, and this continued when seroconverted
subjects were divided into non-progressors and progressors
(Figures 8E,F).
SLEC Frequencies Are Strongly Associated
With CMV IgG Levels Among
Seroconverted Subjects And CMV+
Progressors Harbor the Highest
Frequencies of SLEC and Associated
Chronically-Activated CD8T Cells
To determine if viral exposure was influencing the T cell
changes associated with seroconversion, we tested plasma for
abundance of anti-viral immunoglobulins using ELISA. We then
performed correlations comparing T cell frequency with relative
abundance of viral immunoglobulins as gauged by optical density
values. Neither MAIT cells nor CD127dim Treg-like cells were
correlated with abundance of CMV, EBV VCA and enterovirus
IgG (Figures 9A,D) nor IgM (data not shown). This was not
the case for conventional αβ CD8T cells. We observed a weak
but significant association between EBV VCA IgG and CCR7dim
CD45RA+ CD8T cells (Figure 9B). However, there was no
significant association among this subset with CMV IgG or
enterovirus IgG (Figure 9B), nor any viral IgM tested (data not
shown). Finally, we observed a strong and significant association
among SLEC and CMV IgG, but not with EBV VCA IgG,
enterovirus IgG, nor any viral IgM tested (Figure 9C and data
not shown).
Since the SLEC subset appeared to be strongly influenced
by CMV, we stratified our subjects according to CMV IgG
positivity and then retested the entirety of the CD28– CD8T
cell compartment by ANOVA. We observed that the SLEC
expansion is greatest among CMV+ progressors (Figure 10A).
Furthermore, we observed that the CMV+ progressors possessed
elevated frequencies of additional chronically-stimulated CD28–
subsets (Figures 10B–E). While these lacked the expression
of CD57, they were heterogeneous for CD127 and CD27
expression. In total, these data reveal a relationship among
type 1 diabetes progression, terminally-differentiated effector-
like CD8T cells, and existing cytomegalovirus infection among
at-risk, seroconverted subjects.
DISCUSSION
The etiology of type 1 diabetes remains obscure. This is due, in
part, to the inaccessibility of the target tissue. Indeed, pancreatic
biopsy currently comes with unwanted risk for the donor (52).
Analysis of circulating white blood cells as a proxy for solid tissue
interrogation allows us to apparently circumvent the problem
of pancreas accessibility. Thus, our cross-sectional study was
designed to screen multiple T cell subsets from at-risk subjects
in order to reveal if immune perturbations are associated with
seroconversion and disease progression. To that end, the answer
is a clear “yes.” However, this “indirect” analysis is plagued
by at least two deficiencies. First, in the absence of a defined
causal factor (or set of factors), increases/decreases in frequency
of circulating immune cells cannot be explained satisfactorily
(53, 54). Second, without follow-up longitudinal analysis of these
subjects, such changes in frequency cannot be understood in their
dynamic processional roles through time from seroconversion to
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FIGURE 7 | Frequencies of CD127dim Treg-like cells are positively correlated with CD127bright memory CD4T cells among seroconverted subjects. (A) We observed
no significant correlation among frequencies of CD127dim Treg-like cells and MAIT cells. (B) Although not correlated among AA- subjects, frequencies of CD127bright
memory and CD127dim Treg-like CD4T cells were positively and significantly correlated among seroconverted subjects. (C) Frequencies of CD45RA+, CCR7dim
memory-like CD8T cells and CD127dim Treg-like CD4T cells were not correlated among seroconverted and AA– subjects. (D) Frequencies of SLEC were not
correlated with CD127dim Treg-like CD4T cells in AA– or seroconverted subjects. (E) Frequency of CD45RA+, CCR7dim memory-like CD8T cells are positively
correlated with islet cell antibody (ICA) levels. (F) Frequency of SLEC are positively correlated with harmonized insulinoma antigen 2 (IA-2H) levels. Statistical tests fully
described in section Materials and Methods.
diagnosis. With these concerns in mind, the following discussion
will focus on relevant available reports on comparable immune
cell subsets as mere possibilities, as fundamental mechanistic
explanations are not available.
Due to their unique function, MAIT cells have been examined
in several disease states. Among T1D, the findings are not
consistent. We have previously found no change in proportion
or number of CD8+ MAIT cells from diabetics in relation
to controls (55). Furthermore, we have recently replicated and
extended these findings among a second cohort of age-matched
juvenile T1Ds and controls (in preparation). Alternatively,
Rouxel and colleagues reported reduced frequencies of total
MAIT cells to be associated with T1D (51). In the same
study, they observed no reduction in proportion of total
MAIT cells in their examination of a small cohort of at-risk
subjects acquired from TrialNet. Whether these discrepancies
result from methodological and/or sampling differences is
unclear and independent studies must be conducted for
clarification.
Aside from T1D, reductions in circulating MAIT cell
populations have been associated with enteric fever (56), several
viral infections (57–60), and among other autoimmune diseases
and inflammatory disorders such as MS, SLE, RA, and IBD (61–
64). Such studies have indicated that MAIT cells are prone to
apoptosis in inflammatory milieus, and that reductions in the
periphery may co-occur with elevations or reductions in other
tissues (57, 62–65). Importantly, type I interferons, perturbed
microbiota, viral infection, and increased intestinal permeability
have all been associated with the development of T1D (66–69).
It remains to be determined if and how these factors impact the
MAIT cell lineage and if they are contributing to the deficiencies
we have observed.
Along with reduced frequencies of MAIT cells, we observed
reductions in several CD4T cell subsets, which, although
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FIGURE 8 | Seroconverted subjects possessed elevated ratios of frequency of SLEC to both frequency of CD127dim Treg-like CD4 cells and frequency of MAIT cells.
The ratio of frequency of SLEC to frequency of CD127dim Treg-like cells was significantly elevated among seroconverted subjects (A) and extended into both
non-progressors and progressors (B). We observed no difference in ratios of either MAIT cells (C,D) or CD45RA+, CCR7dim memory-like CD8T cells (E,F) to
CD127dim Treg-like CD4T cells. The ratio of frequency of SLEC to frequency of MAIT cells was significantly elevated among seroconverted subjects (G) and extended
into both non-progressors and progressors (H). For all figures, bars represent median. Statistical tests fully described in section Materials and Methods.
phenotypically diverse, all share the expression of CCR4.
This is not the first report of CCR4 alterations in T1D.
A reduced frequency of CCR4+ CD3+ cells was observed
among recently-diagnosed type 1 diabetics (70). Additionally,
reduced CCR4 expression following Th1 or Th2 polarization
was observed among cord blood T cells from individuals
possessing genetic risk alleles for T1D (71). These intriguing
results suggest that the CCR4 deficiencies we have observed
among seroconverted subjects may have a genetic component
and ultimately originate during thymic selection. While our
study was neither designed nor powered to explore this question
properly, follow-up investigations should be considered highly
relevant.
At this point, we cannot define functional roles for the CCR4-
expressing subsets we found to be diminished. As described
above, there is justification to think that regulatory cells are
residing in the CD127dim compartment. Nevertheless, a recent
examination of TrialNet samples enquiring into FOXP3 and IL-
17-producing CD4T cells did not report reduced frequencies
(72). Due to key methodological differences, it’s uncertain
how much to extend from this study onto ours. Yet, should
we presume that seroconverted subjects are not deficient in
regulatory or Th17 cells (both of which are plausible based upon
phenotype), we are left with likely Th2 or Th22—type cells.
Although relatively unexplored in T1D, Th22-type CD4T cells
have been found in the human gut mucosa (73, 74) and the
cytokine IL-22 plays a key role in intestinal defense and integrity
(75). Alternatively, the Th2 lineage is generally associated with
anti-parasite and allergic responses (76). Interestingly, part of the
hygiene hypothesis suggests that the absence of a manageable
parasite load is a factor driving increases in the prevalence of
autoimmunity (77).
While subset functional status will remain elusive for the time
being, the expression of CCR4 clearly indicates responsiveness
to MDC, TARC, and CKLF1. Thus, we are currently evaluating
plasma from TrialNet subjects for abundance of these and other
factors. Importantly, there is some evidence that MDC may
play a role in T1D. Elevated MDC transcripts have been found
in the duodenal mucosa among T1Ds (78) and MDC can be
produced by human islets exposed to a cocktail of inflammatory
cytokines (79).
Among conventional CD8T cells, our screening for T cell
aberrations revealed two distinct compartments both associated
with islet autoantibody levels. At this point, little can be said
regarding the reduced frequency of the CD45RA+, CCR7dim/−
CD8T cell subsets. While their precise characterization indicates
central of effector memory-type CD8T cells, discussions
of ontogeny, functionality or specificity of these subsets
would be purely speculative and tantamount to hand-waving.
Nevertheless, some compelling observations associated with this
group do stand out for comment. First, the correlation with ICA
levels associates these T cells with beta cell destruction, yet the
populations are not expanded among seroconverted subjects and
are most reduced among non-progressors. This implies that the
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FIGURE 9 | SLEC frequencies are strongly associated with cytomegalovirus IgG levels among seroconverted subjects, but not among controls. We gauged
abundance of anti-viral immunoglobulins using ELISA. We then compared frequencies of T cell subsets with IgG abundance. (A) Frequency of MAIT cells was not
significantly associated with abundance of cytomegalovirus (CMV) IgG, Epstein-Barr Virus viral capsid antigen (EBV VCA) IgG, or enterovirus IgG among
seroconverted subjects and controls. (B) Frequency of CCR7dim, CD45RA+ CD8T cells was significantly associated with EBV VCA IgG among seroconverted
subjects, but not with CMV IgG or enterovirus IgG abundance. (C) Frequency of SLEC was significantly associated with CMV IgG abundance among seroconverted
subjects but not among controls. We observed no significant relationship among SLEC with either EBV VCA IgG or enterovirus IgG. (D) CD127dim Treg-like
CD4T cells were not significantly associated with CMV, EBV VCA, or enterovirus IgG abundance. Statistical tests fully described in section Materials and Methods.
“normal” frequencies observed among the progressors could be
cryptically pathogenic. Second, the modest association with EBV
VCA IgG levels is notable, especially in light of a recent report of
a causal role for EBV in autoimmunity (80). Stratification of our
subjects according to EBV positivity, as we performed for CMV,
did not reveal significant associations with disease progression
(data not shown). Therefore, the overall impact of EBV on the
development of disease at this point is uncertain.
Fortunately, we can be somewhat more definite in the
discussion of the SLEC population, whose phenotype (CD28–,
CD57+, CD27–, and CD127–) is indicative of effector status
and cytotoxic potential. Furthermore, our data demonstrate
that the SLEC subset is strongly associated with CMV IgG
levels. Comparable phenotypes have been associated with
CMV infection previously (81–87). From our stratifications,
we observed that CMV+ progressors possess much higher
frequencies of SLEC and related subsets in comparison to CMV+
AA– and non-progressor subjects. This novel observation links
a cytotoxic CD8T cell subset with disease progression and viral
exposure. The critical question remaining is what is driving this
cellular expansion. An obvious possibility is an acute response
to an active CMV infection. To that end, we did not observe
CMV IgM positivity among any of the subjects in this study.
Nevertheless, we cannot rule out an active viral infection since
we were unable to analyze plasma or circulating leukocytes for
presence and abundance of viral nucleic acids (88). Such an
analysis remains a priority.
In the absence of an active CMV infection, alternate
possibilities exist. Following the initial infection, CMV
establishes latency and a lifelong residence in the host (89).
Over time, reactivation from latency is presumed to drive the
expansion of responding CD8T cells due to chronic antigen
exposure (90, 91). In this scenario, the SLEC expansion may
represent an exhausted T cell response due to elevated or
uncontrolled reactivation of CMV over time. How this could
impact beta cells is unknown. Importantly, we observed a
positive correlation with IA-2 levels and SLEC frequencies
among seroconverted subjects, thereby associating SLEC with
beta cell demise and autoimmunity. Whether SLEC could be
directly or indirectly responsible for beta cell death remains to be
determined. There is in vitro evidence that CMV can infect beta
cells (92). However, pancreatitis is not normally associated with
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FIGURE 10 | SLEC and associated chronically-stimulated CD8T cells are significantly elevated among CMV+ progressors. Subjects were stratified as either positive
or negative for CMV IgG (CMV+ or CMV–). We then reanalyzed the CD28– CD8T cell dataset to check for differences associated with CMV among the AA–,
non-progressor (Non-prog), and progressor (Prog) groups. (A) The SLEC expansion was most prominent among CMV+ progressors. We observed additional
chronically-stimulated CD8T cell subsets that were significantly expanded among the CMV+ progressor group: (B) CD127–, CD27+, CD57–, CD28–; (C) CD127–,
CD27–, CD57–, CD28–; and (D) CD127+, CD27–, CD57–, CD28–. The gating for the subsets in (B–D) is shown in (E). The CMV–, non-progressor that is colored
gray and indicated with an arrow was equivocal for CMV IgG after being tested twice. Bars represent median. Statistical tests fully described in section Materials and
Methods.
CMV infection (93), making the direct lysis of CMV-infected
beta cells less likely. Aside from direct infection, an answer
could be found in the concept of molecular mimicry. It’s been
reported the CMV major capsid protein shares 64% identity and
73% similarity to the dominant epitope peptide of IA-2 (94).
Through that lens, one could imagine the inflated population
we have observed to be a polyclonal pool of effectors, some
“autoreactive.” Such an expansion could explain the precipitous
decline in beta cells that has been observed in the progression
to diagnosed diabetes (95), as well as the negative association
among CMV-specific CD8T cells and c-peptide levels among
diagnosed type 1 diabetics (96).
In summary, the combined results of our T cell analysis
among seroconverted subjects demonstrate reductions of innate-
like, memory and regulatory subsets, with a clear expansion
of a SLEC compartment (see Supplemental Figure 5 for an
interpretation of some of these phenomena). Intriguingly, while
the expansion of the SLEC population is most prominent
among the progressors, the remaining subsets appear to
approach normal mean levels among those same subjects,
albeit somewhat bimodally distributed. The causal foundations
of these observations are not available. However, they do
suggest that measurable and unique immunological changes
occur as one moves toward clinical disease. Thus, assuming
that seroconversion indicates a triggering event that led to beta
cell destruction, all seroconverted subjects share a common
history. Concomitantly, seroconverted subjects also have reduced
frequencies of MAIT cells, CCR4+ CD4T cells, and CD45RA+
memory CD8T cells. For progressors, the advance of beta cell
destruction, which is generally foretold by increasing number of
autoantibody specificities, is then also foretold by recurrence to
relatively normal abundance of these T cell compartments. If,
when, and how these populations contribute to autoimmunity
remains to be determined. Nevertheless, weaving through this
tapestry is the expanded, CMV-associated SLEC compartment,
which is clearly present in progressors as well as some non-
progressors. This expansion may then be viewed as a hit-and-
run or remitting-and-relapsing response to pathogen and/or
autoantigen, theories which have been proposed previously
(97, 98).
While the paradigm described above could be considered
“counterintuitive,” we are wary of talk of intuition in the
absence of data. To that end, future efforts should focus on
two complementary directions. One, longitudinal analysis of
these subjects must be performed to delineate these population
dynamics prior to seroconversion, at seroconversion, and
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closer toward diagnosis. Two, the characterization of the
TCR specificity of the SLEC population, elucidation of the
functional status of the CCR4-expressing CD4T cells, and
exploration of the fate of the MAIT cell lineage are essential to
explicate how the immune system is responding during beta cell
demise. In combination, such an approach should reveal which
environmental determinants are driving T1D.
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